Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice supplementary table

Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure (HF) with

reduced ejection fraction in clinical practice in Spain. Materials & methods: This multicenter cohort

study included subjects aged 50 years or older consecutively hospitalized for HF in internal medicine

departments in Spain. The projected clinical benefits of dapagliflozin were estimated based on results

from the DAPA-HF trial. Results: A total of 1595 patients were enrolled, of whom 1199 (75.2%) were

eligible for dapagliflozin. Within 1 year after discharge, 21.6% of patients eligible for dapagliflozin

were rehospitalized for HF and 20.5% died. Full implementation of dapagliflozin led to an absolute risk

reduction of 3.5% for mortality (number needed to treat = 28) and 6.5% (number needed to treat = 15)

for HF readmission. Conclusion: Treatment with dapagliflozin in clinical practice may markedly reduce

mortality and readmissions for HF.